TOP TEN perturbations for 1430_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1430_at
Selected probe(set): 213921_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1430_at (213921_at) across 6672 perturbations tested by GENEVESTIGATOR:

stem cell differentiation study 59 (iDRG; 12d) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):9.915571
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (iDRG; 12d)
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper.
Control normal embryonic stem cell sample (WA09)
Undifferentiated WA09 embryonic stem cell samples.

stem cell differentiation study 59 (iDRG; 15d) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):9.7641945
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (iDRG; 15d)
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 7 days. Further details are described in the paper.
Control normal embryonic stem cell sample (WA09)
Undifferentiated WA09 embryonic stem cell samples.

stem cell differentiation study 59 (iDRG; 9d) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):9.575066
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (iDRG; 9d)
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 1 day. Further details are described in the paper.
Control normal embryonic stem cell sample (WA09)
Undifferentiated WA09 embryonic stem cell samples.

pancreatic islet study 3 (expanded; PPRF) / normal pancreatic islet sample

Relative Expression (log2-ratio):-8.15896
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (expanded; PPRF)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded according to Pharmaceutical Production Research Facility Protocol (PPRF) for 6 weeks. Expansion phase: Approximately 2,500 islet equivalents were seeded onto 75-cm2 fibronectin-coated tissue culture-treated flasks in a proprietary serum-free medium (PPRF medium). The serum-free PPRF medium was supplemented with 30% serum-free mesenchymal-conditioned medium. When the cell migration resulted in the formation of large-size colonies, the cells were harvested by trypsinization and replated into new tissue culture flasks. Once the cells reached near confluence (80–90%) in monolayer, they were trypsinized, counted, and subcultured at a density of 5,000 cells per cm2. Thereafter, cells were serially passaged using the same protocol.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) / expO ovary cancer study 1 (adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):7.872015
Number of Samples:2 / 4
Experimental expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with transitional cell carcinoma (NOS).
Control expO ovary cancer study 1 (adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with adenocarcinoma (NOS).

stem cell differentiation study 59 (8d) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):7.418524
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (8d)
WA09 embryonic stem cell samples differentiated for 8 days. Further details are described in the paper.
Control normal embryonic stem cell sample (WA09)
Undifferentiated WA09 embryonic stem cell samples.

pancreatic islet study 3 (re-differentiated; PPRF; 2d) / normal pancreatic islet sample

Relative Expression (log2-ratio):-7.3793936
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (re-differentiated; PPRF; 2d)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 2 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) / expO ovary cancer study 1 (mixed epithelial tumor; primary)

Relative Expression (log2-ratio):7.370263
Number of Samples:2 / 3
Experimental expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with transitional cell carcinoma (NOS).
Control expO ovary cancer study 1 (mixed epithelial tumor; primary)
Primary tumor tissue samples obtained from the ovary of patients with mixed epithelial tumor.

pancreatic islet study 3 (re-differentiated; PPRF; 4d) / normal pancreatic islet sample

Relative Expression (log2-ratio):-7.2720566
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (re-differentiated; PPRF; 4d)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 4 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) / expO ovary cancer study 1 (carcinoma, NOS; primary)

Relative Expression (log2-ratio):7.1980686
Number of Samples:2 / 2
Experimental expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with transitional cell carcinoma (NOS).
Control expO ovary cancer study 1 (carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with carcinoma (NOS).